phase readout
saveNCT05833438: Venetoclax in Combination With 5 Days Azacitidine in Untreated AML Patients, Not Eligible for Standard Induction Therapy
ACTIVE_NOT_RECRUITINGupdated 20d ago
community read0 votes
Sponsor: University of Leipzig. Phase: PHASE2. Conditions: Acute Myeloid Leukemia (AML)
view source ↗
comments(0)
5-min edit window · permanent after that